Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 61
Filtrar
Mais filtros

Coleção SES
Intervalo de ano de publicação
1.
Antimicrob Agents Chemother ; 60(1): 686-8, 2016 01.
Artigo em Inglês | MEDLINE | ID: mdl-26552984

RESUMO

In this work, we demonstrate that the fosI gene encodes a predicted small protein with 134 amino acids and determines reduced susceptibility to fosfomycin. It raised the MIC from 0.125 to 6 µg/ml when the pBRA100 plasmid was introduced into Escherichia coli TOP10 and to 16 µg/ml when the gene was cloned into the pBC_SK(-) vector and expressed in E. coli TOP10.


Assuntos
Antibacterianos/farmacologia , Farmacorresistência Bacteriana/genética , Escherichia coli/genética , Fosfomicina/farmacologia , Integrons , Sequência de Aminoácidos , Escherichia coli/efeitos dos fármacos , Escherichia coli/metabolismo , Expressão Gênica , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , Plasmídeos/química , Plasmídeos/metabolismo , Alinhamento de Sequência , Transformação Bacteriana
2.
Brain Inj ; 28(9): 1223-5, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24910931

RESUMO

BACKGROUND: A 36-year-old immunocompetent woman with a posterior fossa arteriovenous malformation (PF-AVM) and hydrocephalus presented with low fever and mental confusion 4 days after ventriculoperitoneal shunting (VPS). METHODS: Cerebrospinal fluid (CSF) and ventricular catheter tip cultures isolated Corynebacterium sp. Similar to previous cases in the literature, species determination was not possible. However, the antibiotic sensitivity profile of this isolate suggested Corynebacterium jeikeium. Conversion to external ventricular drainage (EVD) was done and intravenous vancomycin was administered for 21 days. RESULTS AND CONCLUSIONS: The patient showed progressive improvement. Since the first CSF shunt infection caused by Corynebacterium sp., 16 other cases in the literatures have been reported. Additionally, this study reports the difficulties in recognizing CSF shunt infection caused by this agent and the possible clinical or laboratory patterns as observed in the literature.


Assuntos
Confusão/microbiologia , Infecções por Corynebacterium/diagnóstico , Corynebacterium/isolamento & purificação , Febre/microbiologia , Hidrocefalia/microbiologia , Derivação Ventriculoperitoneal/efeitos adversos , Adulto , Antibacterianos/administração & dosagem , Cateterismo/efeitos adversos , Confusão/tratamento farmacológico , Confusão/etiologia , Infecções por Corynebacterium/tratamento farmacológico , Drenagem , Feminino , Febre/tratamento farmacológico , Febre/etiologia , Humanos , Hidrocefalia/tratamento farmacológico , Hidrocefalia/etiologia , Resultado do Tratamento , Vancomicina/administração & dosagem
3.
Drug Deliv Transl Res ; 10(2): 403-412, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31701487

RESUMO

Leishmaniasis occurs in the five continents and represents a serious public health challenge, but is still a neglected disease, and the current pharmacological weaponry is far from satisfactory. Triglyceride-rich nanoparticles mimicking chylomicrons (TGNP) behave metabolically like native chylomicrons when injected into the bloodstream. Previously we have shown that TGNP as vehicle to amphothericin B (AB) for treatment of fungi infection showed reduced renal toxicity and lower animal death rates compared to conventional AB. The aim of the current study was to test the tolerability and effectiveness of the TGNP-AB preparation in a murine model of Leishmania amazonensis infection. The in vitro assays determined the cytotoxicity of TGNP-AB, AB, and TGNP in macrophages and promastigote forms and the leishmanicidal activity in infected macrophages. The in vivo toxicity tests were performed in healthy mice with increasing doses of TGPN-AB and AB. Then, animals were treated with 2.5 mg/kg/day of AB, 17.5 mg/kg/day of TGNP-AB, or TGNP three times a week for 4 weeks. TGNP-AB formulation was less cytotoxic for macrophages than AB. TGNP-AB was more effective than AB against the promastigotes forms of the parasite and more effective in reducing the number of infected macrophages and the number of amastigotes forms per cell. TGNP-AB-treated animals showed lower hepatotoxicity. In addition, TGNP-AB group showed a marked reduction in lesion size on the paws and parasitic load. The TGNP-AB preparation attained excellent leishmanicidal activity with remarkable lower drug toxicity at very high doses that, due to the toxicity-buffering properties of the nanocarrier, become fully tolerable.


Assuntos
Anfotericina B/administração & dosagem , Antiprotozoários/administração & dosagem , Quilomícrons/química , Leishmaniose Cutânea/tratamento farmacológico , Triglicerídeos/química , Anfotericina B/química , Anfotericina B/farmacologia , Animais , Antiprotozoários/química , Antiprotozoários/farmacologia , Linhagem Celular , Modelos Animais de Doenças , Composição de Medicamentos , Feminino , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Macrófagos/parasitologia , Camundongos , Camundongos Endogâmicos BALB C , Mimetismo Molecular , Nanopartículas , Carga Parasitária
4.
Am J Trop Med Hyg ; 101(2): 402-403, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31219006

RESUMO

Immunosuppressive treatments for rheumatic diseases present special problems in areas endemic for chronic infectious diseases because of the possibility of reactivation. Leishmaniasis is a significant neglected tropical disease caused by different species of protozoan parasites within the genus Leishmania. Amastigotes live as intracellular parasites in a variety of mammalian cells, most notably within phagocytes such as macrophages, and residual parasites can persist even after treatment and healing of the lesions. We herein report a case of relapsing mucosal leishmaniasis after aggressive immunotherapy for ankylosing spondylitis, with requirement for secondary prophylaxis with amphotericin B to prevent reactivation. This approach can be necessary for patients from endemic areas of tegumentary leishmaniasis, who will undergo aggressive immunotherapy.


Assuntos
Anfotericina B/administração & dosagem , Antiprotozoários/administração & dosagem , Leishmaniose Mucocutânea/tratamento farmacológico , Prevenção Secundária/métodos , Espondilite Anquilosante/imunologia , Espondilite Anquilosante/terapia , Adulto , Humanos , Imunossupressores/efeitos adversos , Imunoterapia , Masculino , Recidiva , Espondilite Anquilosante/complicações
5.
Front Immunol ; 10: 920, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31114579

RESUMO

Objectives: To compare microscopic and immunologic features in the spleens of patients who died of pulmonary hemorrhage and shock caused by leptospirosis (11 cases) or Gram-positive/-negative bacterial septic shock (10 cases) to those from control spleens (12 cases from splenectomy). Methodology: Histological features in the red pulp and white pulp were analyzed using archived samples by a semi quantitative score. Immunohistochemistry was used for the recognition of immune cell markers, cytokines, caspase-3 and Leptospira antigens. Results: The control group differed significantly from the leptospirosis and septic shock patients which demonstrate strong similarities: diffuse congestion in the red pulp with a moderate to intense infiltration of plasma cells and polymorphonuclear cells; follicles with marked atrophy; high density of CD20+ cells; low density of NK, TCD4+ and active caspase-3 positive cells and strong expression of IL-10; leptospirosis patients had higher S100 and TNF-α positive cells in the spleen than the other groups. Conclusion: The results suggest that an immunosuppressive state develops at the terminal stage of severe leptospirosis with pulmonary hemorrhage and shock similar to that of patients with septic shock, with diffuse endothelial activation in the spleen, splenitis, and signs of disturbance in the innate and adaptive immunity in the spleen. The presence of leptospiral antigens in 73% of the spleens of the leptospirosis patients suggests the etiological agent contributes directly to the pathogenesis of the lesions. Our results support therapeutic approaches involving antibiotic and immunomodulatory treatments for leptospirosis patients and suggest that leptospirosis patients, which are usually young men with no co-morbidities, form a good group for studying sepsis and septic shock.


Assuntos
Antígenos de Bactérias/imunologia , Tolerância Imunológica , Leptospira/imunologia , Leptospirose/imunologia , Choque Séptico/imunologia , Baço/imunologia , Adulto , Feminino , Humanos , Leptospirose/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença , Choque Séptico/patologia , Baço/patologia
6.
Acta Trop ; 105(1): 1-9, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17884002

RESUMO

Leishmaniasis causes significant morbidity and mortality and thus constitutes a serious public health problem. Even though it has long been endemic in developing countries, in recent years the economic globalization and the increased volume of international travel have extended its prevalence in developed countries. In addition, native populations may be exposed to the infection through blood transfusion and the use of blood products produced from infected asymptomatic individuals. Mucosal leishmaniasis (ML) is a chronic form of this infection, which attacks the mucosa. In most cases this form of leishmaniasis results from the metastatic spread of Leishmania (Viannia) braziliensis from cutaneous lesions. It is a healthcare issue because of its wide demographic distribution, its association with significant morbidity levels, and because of the pressing concern that tourists who travel to endemic areas might present the disease even years later. The treatment currently available for ML is based on drugs such as pentavalent antimony-containing compounds, amphotericin B deoxycholate and pentamidine and often guarantees a satisfactory clinical response. Nevertheless, it also frequently provokes serious side effects. This review offers a critical analysis of the drugs now available for the treatment of ML as also of the future prospects for the treatment of the disease.


Assuntos
Antiprotozoários/uso terapêutico , Leishmania braziliensis/isolamento & purificação , Leishmaniose Mucocutânea/tratamento farmacológico , Leishmaniose Mucocutânea/epidemiologia , Anfotericina B/uso terapêutico , Animais , Antimônio/uso terapêutico , Ácido Desoxicólico/uso terapêutico , Países Desenvolvidos , Países em Desenvolvimento , Combinação de Medicamentos , Doenças Endêmicas , Humanos , Leishmaniose Mucocutânea/parasitologia , Pentamidina/uso terapêutico , Viagem
7.
Rev Inst Med Trop Sao Paulo ; 50(2): 123-7, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18488094

RESUMO

Virus-Associated Hemophagocytic Syndrome (VAHS) is a severe hematological disorder related to some viral infections. It is an illness characterized by persistent fever, pancytopenia, splenomegaly, hyperferritinemia and, the most important, hemophagocytosis observed in the bone marrow, liver and/or lymph nodes. VAHS associated with hepatitis A virus infection is rarely described, despite the high incidence of this viral infection in the population in general. There is no consensus in the literature regarding the optimal treatment of VAHS. In this article the clinical features, presumed pathogenesis, diagnostic criteria and treatment of VAHS are discussed, including description of cases of VAHS related to hepatitis A virus infection found in the medical literature.


Assuntos
Hepatite A/complicações , Linfo-Histiocitose Hemofagocítica/virologia , Adulto , Feminino , Hepatite A/diagnóstico , Anticorpos Anti-Hepatite A/sangue , Humanos , Imunoglobulina M/sangue , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Linfo-Histiocitose Hemofagocítica/diagnóstico , Linfo-Histiocitose Hemofagocítica/tratamento farmacológico
8.
Autops Case Rep ; 8(2): e2018028, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30584503

RESUMO

In the advanced stage of AIDS, the diagnosis of the opportunistic infections may be challenging due to the high risk of performing invasive diagnostic methods in a patient with a critical clinical condition, as well as the correct interpretation of the results of microbiological exams. One of the challenges for the diagnosis and treatment of the opportunistic infections is that they may occur concomitantly in the same patient and they may mimic each other, leading to a high discrepancy between clinical and autopsy diagnoses. We describe the case of a 52-year-old man who was hospitalized because of weight loss, anemia, cough, and hepatosplenomegaly. During the investigation, the diagnosis of AIDS was made, and the patient developed respiratory failure and died on the fourth day of hospitalization. At autopsy, disseminated non-tuberculosis mycobacteriosis was found, affecting mainly the organs of the reticuloendothelial system. Also, severe and diffuse pneumonia caused by multiple agents (Pneumocystis jirovecii , Histoplasma capsulatum, suppurative bacterial infection, non-tuberculosis mycobacteria, and cytomegalovirus) was seen in a morphological pattern that could be called "collision pneumonia." The lesson from this case, revealed by the autopsy, is that in advanced AIDS, patients often have multiple opportunistic infections, so the principle of Ockham's razor-that a single diagnosis is most likely the best diagnosis-fails in this clinical context.

9.
Autops Case Rep ; 8(1): e2018012, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29588907

RESUMO

Extracerebral toxoplasmosis, with pulmonary involvement and shock, is a rare form of toxoplasmosis in patients with advanced AIDS. It can mimic pneumocystosis, histoplasmosis, and disseminated tuberculosis, and should be considered in the differential diagnosis of causes of respiratory failure and fulminant disease in this group of individuals, especially in areas where the Toxoplasma gondii infection is highly prevalent and in those without proper use of antimicrobial prophylaxis. We report the case of a 46-year-old male patient who presented to the emergency department with uremia, requiring urgent dialysis. During the laboratorial investigation, the patient had confirmed HIV infection, with a low CD4+ peripheral T-cell count (74 cells/µL). During hospitalization, the patient presented drug-induced hepatitis due to trimethoprim/sulfamethoxazole in a prophylactic dose, requiring interruption of this medication. On the 55th day of hospitalization, the patient developed refractory shock and died. At the autopsy, disseminated toxoplasmosis with encephalitis and severe necrotizing pneumonia were diagnosed, with numerous tachyzoites in the areas of pulmonary necrosis.

10.
Am J Trop Med Hyg ; 77(2): 266-74, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17690398

RESUMO

Mucosal leishmaniasis (ML) is an important endemic disease and public-health problem in underdeveloped countries because of its significant morbidity and mortality. Increases in ecological tourism have extended this problem to developed countries. This form of leishmaniasis, caused by reactivation after primary cutaneous lesion, has a natural history of progressive destruction of the nasal septa and soft and hard palates, causing facial disfiguration and leading to respiratory disturbances. Treatment of ML, based on several therapies, depends on use of toxic compounds, and few drugs have emerged over the past 40 years. Drug resistance has increased, and the cure rate is no better than 70% in the largest studies. Despite these data, there has been no systematic review of therapies used to treat this important tropical disease. The aim of this study is to determine the best drug management for treatment of ML in Latin America based on the best studies offered by the medical literature. The MEDLINE, LILACS, EMBASE, Web of Science, and Cochrane Library databases were searched to identify articles related to ML and therapy. The studies were independently selected by 2 authors. Articles with sufficient data for cure and treatment failures, internal and external validity information, and > 4 patients in each treatment were included. Validation of this systematic review was based on guidelines to guarantee quality; 22 articles met our inclusion criteria. Stibogluconate achieved a 51% cure rate (76/150 patients), and 88% of patients treated with meglumine were cured (121 patients). Pentamidine and amphotericin were as effective as meglumine. Use of itraconazole and other therapies (pentoxifylline, allopurinol, or interferon-gamma) was controversial, and numbers of patients in some studies were insufficient for statistical analysis. Meglumine may be the drug of choice in the treatment of ML, as it offers similar cure rates when compared with amphotericin B and pentamidine. Cost, adverse effects, local experience, and availability of drugs to treat ML are strong points to be considered before determining the best management of this disease, especially in developing countries.


Assuntos
Antiprotozoários/uso terapêutico , Leishmania/crescimento & desenvolvimento , Leishmaniose Mucocutânea/tratamento farmacológico , Anfotericina B/uso terapêutico , Animais , Gluconato de Antimônio e Sódio/uso terapêutico , Humanos , Itraconazol/uso terapêutico , América Latina , Leishmaniose Mucocutânea/parasitologia , Meglumina/uso terapêutico , Paromomicina/uso terapêutico , Pentamidina/uso terapêutico
12.
Rev Inst Med Trop Sao Paulo ; 48(5): 301-2, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17086322

RESUMO

Subcutaneous candidal abscess is a very rare infection even in immunocompromised patients. Some cases are reported when breakdown in the skin occurs, as bacterial cellulites or abscess, iatrogenic procedures, trauma and parenteral substance abuse. We describe a case of Candida albicans subcutaneous abscess without fungemia, which can be associated with central venous catheter.


Assuntos
Abscesso/microbiologia , Candidíase Cutânea/microbiologia , Cateterismo Venoso Central/efeitos adversos , Abscesso/terapia , Adulto , Antifúngicos/uso terapêutico , Candida albicans , Candidíase Cutânea/terapia , Desbridamento , Fluconazol/uso terapêutico , Humanos , Masculino
13.
Rev Inst Med Trop Sao Paulo ; 48(4): 233-5, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17119683

RESUMO

Frontal osteomyelitis is a rare complication of sinusitis. Common intracranial complications of the frontal osteomyelitis are meningitis, epidural empyema, subdural empyema and brain abscess. We described a case of frontal osteomyelitis with brain abscess caused by Staphylococcus aureus with improve after needle aspiration and antibiotics to brain abscess for eight weeks and for chronic osteomyelitis for four months.


Assuntos
Abscesso Encefálico/microbiologia , Sinusite Frontal/complicações , Osteomielite/complicações , Infecções Estafilocócicas/complicações , Staphylococcus aureus/isolamento & purificação , Adulto , Antibacterianos/uso terapêutico , Abscesso Encefálico/terapia , Doença Crônica , Clindamicina/uso terapêutico , Drenagem , Feminino , Osso Frontal , Humanos , Osteomielite/tratamento farmacológico , Osteomielite/microbiologia , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia , Tomografia Computadorizada por Raios X
14.
Braz J Infect Dis ; 20(5): 476-81, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27542867

RESUMO

Clostridium difficile is a leading cause of diarrhea in hospitalized patients worldwide. While metronidazole and vancomycin are the most prescribed antibiotics for the treatment of this infection, teicoplanin, tigecycline and nitazoxanide are alternatives drugs. Knowledge on the antibiotic susceptibility profiles is a basic step to differentiate recurrence from treatment failure due to antimicrobial resistance. Because C. difficile antimicrobial susceptibility is largely unknown in Brazil, we aimed to determine the profile of C. difficile strains cultivated from stool samples of inpatients with diarrhea and a positive toxin A/B test using both agar dilution and disk diffusion methods. All 50 strains tested were sensitive to metronidazole according to CLSI and EUCAST breakpoints with an MIC90 value of 2µg/mL. Nitazoxanide and tigecycline were highly active in vitro against these strains with an MIC90 value of 0.125µg/mL for both antimicrobials. The MIC90 were 4µg/mL and 2µg/mL for vancomycin and teicoplanin, respectively. A resistance rate of 8% was observed for moxifloxacin. Disk diffusion can be used as an alternative to screen for moxifloxacin resistance, nitazoxanide, tigecycline and metronidazole susceptibility, but it cannot be used for testing glycopeptides. Our results suggest that C. difficile strains from São Paulo city, Brazil, are susceptible to metronidazole and have low MIC90 values for most of the current therapeutic options available in Brazil.


Assuntos
Antibacterianos/farmacologia , Clostridioides difficile/efeitos dos fármacos , Carga Bacteriana , Brasil , Clostridioides difficile/isolamento & purificação , Infecções por Clostridium/microbiologia , Contagem de Colônia Microbiana/métodos , Testes de Sensibilidade a Antimicrobianos por Disco-Difusão/métodos , Ensaio de Imunoadsorção Enzimática , Feminino , Fluoroquinolonas/farmacologia , Humanos , Masculino , Metronidazol/farmacologia , Pessoa de Meia-Idade , Minociclina/análogos & derivados , Minociclina/farmacologia , Moxifloxacina , Nitrocompostos , Valores de Referência , Reprodutibilidade dos Testes , Teicoplanina/farmacologia , Tiazóis/farmacologia , Tigeciclina , Vancomicina/farmacologia
15.
Microb Drug Resist ; 22(4): 321-7, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26670152

RESUMO

Plasmid-mediated AmpC ß-lactamases (PMACBLs) in Enterobacteriaceae encode resistance to third-generation cephalosporins, and these can mediate carbapenem resistance when associated with porin loss. However, no standardized phenotypic method is available for detecting these enzymes in the clinical microbiology laboratory. Limited data are available concerning the frequency of PMACBLs in Enterobacteriaceae in Brazil. This study was conducted in response to an increased cefoxitin (CFO) resistance rate of 3.7% in Escherichia coli isolates from urine samples from patients with suspected urinary tract infections during 2010. We collected 2,266 E. coli isolates prospectively during January 2012. A total of 109 (4.8%) isolates were nonsusceptible to CFO. These strains were further examined using multiplex PCR for the presence of genes encoding PMACBLs and using inhibitor assays with CFO and ceftazidime (CAZ) disks with and without phenylboronic acid. Pulsed-field gel electrophoresis was used to evaluate clonal dissemination. Genes encoding PMACBLs were detected in 1.8% of the isolates from inpatients and 0.46% of isolates from outpatients. The most prevalent gene was blaCMY-2 and blaCMY-4 was also detected. The phenotypic analysis showed 100% sensitivity and specificity for CMY-2 and CMY-4 when CFO-resistant isolates with a minimum zone diameter difference of 5 mm for CAZ or CAZ and CFO were considered positive. Although most of the isolates were nonclonal, one clonal group with two isolates was observed. Thus, the most frequent PMACBL in E. coli from São Paulo, Brazil is CMY-2, and both clonal and plasmid-mediated dissemination occur.


Assuntos
Proteínas de Bactérias/genética , Resistência às Cefalosporinas/genética , Infecções por Escherichia coli/epidemiologia , Escherichia coli/genética , Plasmídeos/metabolismo , Infecções Urinárias/epidemiologia , beta-Lactamases/genética , Idoso , Antibacterianos/farmacologia , Proteínas de Bactérias/classificação , Brasil/epidemiologia , Cefoxitina/farmacologia , Eletroforese em Gel de Campo Pulsado , Escherichia coli/classificação , Escherichia coli/efeitos dos fármacos , Escherichia coli/isolamento & purificação , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/urina , Feminino , Expressão Gênica , Transferência Genética Horizontal , Humanos , Incidência , Pacientes Internados , Masculino , Epidemiologia Molecular , Reação em Cadeia da Polimerase Multiplex , Pacientes Ambulatoriais , Filogenia , Plasmídeos/química , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologia , Infecções Urinárias/urina , beta-Lactamases/classificação
16.
Urology ; 86(3): 492-7, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26163810

RESUMO

OBJECTIVE: To analyze and compare the etiological uropathogens and the susceptibility profile findings on urine culture between sporadic cases of community-acquired, uncomplicated urinary tract infection (UTI) and recurrent UTI cases in women. MATERIALS AND METHODS: We retrospectively analyzed the clinical data of 1629 women with uncomplicated UTI evaluated at our hospital between January 2007 and December 2012. Patients were divided into 2 groups: (1) no recurrent UTI and (2) recurrent UTI. We analyzed the microbiological findings and compared susceptibility profiles between groups. RESULTS: A total of 420 women were included. Group 1 had 233 (55.5%) patients and group 2 had 187 (44.5%). Escherichia coli was the most common agent in both groups (76.4% and 74.3%, respectively; P = .625), whereas Staphylococcus saprophyticus (8.2%) was the second most common in group 1, and Enterococcus faecalis was the second most common in group 2 (8.0%). Nitrofurantoin was the only oral agent that maintained the susceptibility profile in both groups (87.1% and 88.7%, respectively; P = .883). For E coli infections, only nitrofurantoin and amoxicillin/clavulanate maintained susceptibility rates more than 90% in both groups. CONCLUSION: UTI episodes in patients with recurrent UTI had similar bacterial spectra, but different susceptibility profiles compared with those from patients with nonrecurrent infections. The susceptibility rate for nitrofurantoin in patients with recurrent UTI remained high and comparable to the observed in patients with sporadic UTI, reinforcing its indication for empirical treatment while waiting for urine culture results.


Assuntos
Anti-Infecciosos Urinários/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Farmacorresistência Bacteriana , Enterococcus faecalis/isolamento & purificação , Escherichia coli/isolamento & purificação , Feminino , Humanos , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Nitrofurantoína/uso terapêutico , Recidiva , Estudos Retrospectivos , Fatores de Risco , Staphylococcus saprophyticus/isolamento & purificação , Adulto Jovem
17.
Braz J Infect Dis ; 7(1): 62-8, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12807692

RESUMO

We made an open label, multicenter, non-comparative study to assess the efficacy and safety of oral gatifloxacin, 400 mg PO given once-daily during 7 to 14 days for the treatment of adult outpatients with community-acquired pneumonia at five Brazilian medical facilities. Among the 86 subjects available for clinical evaluation, 84 (98%) were cured. The bacteriological eradication and presumed eradication rate was 98% (52/53) among the 44 (51%) patients who were bacteriologically evaluated. Drug-related adverse events were reported by 27% of the patients, diarrhea being the most frequent, occurring in 12% of patients. Adverse events were considered mild (89%) or moderate (11%). We conclude that a 7-14 day course of gatifloxacin, 400 mg PO given once daily is safe and effective for the treatment of community-acquired pneumonia. The drug had a favorable safety profile and a good clinical and bacteriological efficacy.


Assuntos
Anti-Infecciosos/administração & dosagem , Fluoroquinolonas , Pneumonia Bacteriana/tratamento farmacológico , Administração Oral , Adolescente , Adulto , Anti-Infecciosos/efeitos adversos , Brasil , Infecções Comunitárias Adquiridas/tratamento farmacológico , Infecções Comunitárias Adquiridas/microbiologia , Feminino , Gatifloxacina , Haemophilus influenzae/efeitos dos fármacos , Humanos , Masculino , Pneumonia Bacteriana/microbiologia , Streptococcus pneumoniae/efeitos dos fármacos , Resultado do Tratamento
18.
Antibiotics (Basel) ; 3(1): 98-108, 2014 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-27025737

RESUMO

Uncomplicated urinary tract infections (UTI) in women are very common. Regular analysis of bacterial flora is important to formulate updated guidelines. The objective of this study is to determine and compare the microbiology of UTIs and their susceptibility patterns in a quaternary care hospital. In a seven-year review, the urine culture results of 480 female patients with uncomplicated UTIs were analyzed. Patients were divided into three groups according to their diagnosis and treatment characteristics: Group 1, cystitis at outpatient basis; group 2, cystitis at the Emergency Unit; and group 3, pyelonephritis. Group 1 included older patients, with a higher incidence of concomitant diabetes mellitus and recurrent UTIs. E. coli was the most common pathogen, responsible for 75.1% of cases, mainly for pyelonephritis (87.3%). Of the oral antimicrobials tested for cystitis, amoxicillin/clavulanate and nitrofurantoin had the highest susceptibility profiles (84.4% and 87.3%, respectively). For E. coli only, their susceptibility profiles were as high as 90.8% and 97.4%, respectively. For pyelonephritis treatment, fluoroquinoles had a susceptibility profile <90%, while ceftriaxone and gentamicin had susceptibility >90%. Uncomplicated UTI treatment is becoming more challenging because the susceptibility profiles of oral antimicrobials are increasingly resistant. In our environment, cystitis can still be managed with nitrofurantoin. Uncomplicated pyelonephritis should be managed with ceftriaxone or gentamicin.

19.
Trans R Soc Trop Med Hyg ; 108(3): 176-8, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24535153

RESUMO

BACKGROUND: Studies assessing the efficacy of liposomal amphotericin B (LAB) in the treatment of patients with mucosal leishmaniasis (ML) are very scarce in the literature and an optimal dose regimen has not yet been defined. METHODS: We performed a retrospective and descriptive analysis from records of 16 patients with ML treated with LAB. The mean daily dose of LAB was 2.5 mg/kg/day. RESULTS: Healing of the lesion was observed in 14 (88%) of the 16 patients. The mean cumulative doses, excluding the two treatment failures, were 2265 mg and 33 mg/kg. CONCLUSION: Liposomal amphotericin B in the cumulative dose of 30 to 35 mg/kg was able to achieve 100% effectiveness.


Assuntos
Anfotericina B/uso terapêutico , Antiprotozoários/uso terapêutico , Leishmaniose Mucocutânea/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
20.
Am J Trop Med Hyg ; 91(1): 81-3, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24732458

RESUMO

Mucosal leishmaniasis (ML) is a chronic form of tegumentary leishmaniasis, which causes destructive lesions of nasal, pharyngeal, and laryngeal mucosa. We describe a case of leishmaniasis reactivation with simultaneous cutaneous and mucosal forms in a renal transplanted patient with no history of prior leishmaniasis. Reactivation after renal transplantation was not reported in Brazil. A 67-year-old woman receiving prednisone 20 mg/day, tacrolimus 1 mg/day, and mycophenolic acid 360 mg/day presented with nose edema with erythema and cutaneous lesions. Amastigotes were identified on biopsies and the polymerase chain reaction confirmed Leishmania (Viannia) braziliensis. The patient was treated with liposomal amphotericin B but died 3 weeks after as a result of bacterial septic shock. In conclusion, tegumentary leishmaniasis can reactivate with simultaneous cutaneous and mucosal forms in a renal transplanted patient during the immunosuppressant therapy.


Assuntos
Imunossupressores/efeitos adversos , Transplante de Rim , Leishmania braziliensis/fisiologia , Leishmaniose Mucocutânea/etiologia , Idoso , Anfotericina B/uso terapêutico , Antiprotozoários/uso terapêutico , Evolução Fatal , Feminino , Humanos , Leishmania braziliensis/efeitos dos fármacos , Leishmania braziliensis/patogenicidade , Leishmaniose Mucocutânea/tratamento farmacológico , Falha de Tratamento
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa